Диссертация (1174247), страница 19
Текст из файла (страница 19)
1953 May; 39(5):368–76.123138.Senatore G. Role of transtelephonic electrocardiographic monitoring indetecting short-term arrhythmia recurrences after radiofrequency ablation inpatients with atrial fibrillation / Senatore G., Stabile G., Bertaglia E., et al.
// J.Am. Coll. Cardiol. 2005 Mar 15; 45 (6):873–6.139.Senni M. New strategies for heart failure with preserved ejection fraction:the importance of targeted therapies for heart failure phenotypes / Senni M.,Paulus W., Gavazzi A., et al. // Eur Heart J. 2014 Oct 21; 35(40):2797–815.140.Singh B. Amiodarone versus sotalol for atrial fibrillation / Singh B., SinghS., Reda D., et al. // N Engl J Med 2005; 352:1861–72.141.Steven D.
What is the real atrial fibrillation burden after catheter ablationof atrial fibrillation? A prospective rhythm analysis in pacemaker patients withcontinuous atrial monitoring / Steven D., Rostock T., Lutomsky B., et al. // EurHeart J. 2008 Apr; 29(8):1037–42.142.Taylor A. Combination of isosorbide dinitrate and hydralazine in HFblackswith heart failure / Taylor A., Ziesche S., Yancy C., et al. // N Engl J Med, 2004;351:2049–57.143.Tedrow U.
The long- and short-term impact of elevated body mass indexon the risk of new atrial fibrillation the WHS (Women’s Health Study) / TedrowU., Conen D., Ridker P., et al. // J Am Coll Cardiol. 2010; 55:2319–2327.144.Thamilarasan M. Left ventricular diastolic dysfunction in lone atrialfibrillation determined by Doppler tissue imaging of mitral annular motion /Thamilarasan M., Grimm R., Rodriguez L., et al.
// Am J Cardiol. 2000 Nov 1;86(9):1026–9.145.lateThemistoclakis S. Clinical predictors and relationship between early andatrialtachyarrhythmiasafterpulmonaryveinantrumisolation/Themistoclakis S., Schweikert R., Saliba W., et al. // Heart Rhythm 2008; 5:679–685.146.The CONSENSUS Trial Study Group. Effects of enalapril on mortality insevere congestive heart failure. Results of the Cooperative North ScandinavianEnalapril Survival Study (CONSENSUS) // N Engl J Med 1987; 316:1429–35.124147.Tsang T. Left ventricular diastolic dysfunction as a predictor of the firstdiagnosed nonvalvular atrial fibrillation in 840 elderly men and women / TsangT., Gersh B., Appleton C., et al.
// J Am Coll Cardiol. 2002.148.Tsang T. Left atrial volume as a morphophysiologic expression of leftventricular diastolic dysfunction and relation to cardiovascular risk burden /Tsang T., Barnes M., Gersh B., et al. // Am J Cardiol 2002; 90: 1284–9.149.Tsang T. Risks for atrial fibrillation and congestive heart failure in patients>/= 65 years of age with abnormal left ventricular diastolic relaxation /Tsang T.,Barnes M., Gersh B., et al.
// Am J Cardiol. 2004; 93:54–58.150.Van Veldhuisen D. Beta-blockade with nebivolol in elderly heart failurepatients with impaired and preserved left ventricular ejection fraction: data fromSENIORS (Study of Effects of Nebivolol Intervention on Outcomes andRehospitalization in Seniors with Heart Failure) / Van Veldhuisen D., CohenSolal A., Böhm M., et al. // Journal of the American College of Cardiology, vol.53, no. 23, pp. 2150–2158, 2009.151.Vasamreddy C. Predictors of recurrence following catheter ablation ofatrial fibrillation using an irrigated-tip ablation catheter /Vasamreddy C., LickfettL., Jayam V., et al. // J Cardiovasc Electrophysiol 2004; 15:692–697.152.Verma A. Approaches to catheter ablation for persistent atrial fibrillation /Verma A., Jiang C., Betts T., et al.
// N Engl J Med 2015; 372:1812–1822.153.Verma A. Response of atrial fibrillation to pulmonary vein antrum isolationis directly related to resumption and delay of pulmonary vein conduction /VermaA., Kilicaslan F., Pisano E., et al. // Circulation. 2005 Aug 2; 112(5):627–35.154.Weerasooriya R. Catheter ablation for atrial fibrillation: are resultsmaintained at 5 years of follow-up? / Weerasooriya R., Khairy P., Litalien J., etal.
// J Am Coll Cardiol. 2011 Jan 11; 57(2):160–6.155.Wilber D. Comparison of antiarrhythmic drug therapy and radiofrequencycatheter ablation in patients with paroxysmal atrial fibrillation: a randomizedcontrolled trial / Wilber D., Pappone C., Neuzil P., et al. // JAMA 2010;303:33340.125156.Wilke T. Incidence and prevalence of atrial fibrillation: an analysis basedon 8,3 million patients/ Wilke T., Groth A., Mueller S., et al. // Europace. 2013;15 (4): 486–93.157.Wokhlu A. Long-term quality of life after ablation of atrial fibrillation theimpact of recurrence, symptom relief, and placebo effect /Wokhlu A., MonahanK., Hodge D., et al. // J Am Coll Cardiol. 2010 May 25;55(21):2308–16.158.Wylie Jr J.
Left atrial function and scar after catheter ablation of atrialfibrillation / Wylie Jr J., Peters D., Essebag V., et al. // Heart Rhythm 2008;5:656–62.159.Wyse D. Atrial fibrillation: a perspective: thinking inside and outside thebox / Wyse D., Gersh B. // Circulation. 2004 Jun 29;109(25):3089–95.160.Xiong B. The Effect of Catheter Ablation on Left Atrial Size and Functionfor Patients with Atrial Fibrillation: An Updated Meta-Analysis /Xiong B., Li D.,Wang J., et al. // PLoS One.
2015; 10(7): e0129274.161.Yamamoto K. Analysis of left ventricular diastolic function / YamamotoK., Redfield M., Nishimura R. // Heart. – 1996. – V. 75. – P. 27–35.162.Yamamoto K. Effects of carvedilol on heart failure with preserved ejectionfraction: the Japanese Diastolic Heart Failure Study (J-DHF) / Yamamoto K.,Origasa H., Hori M., et al. // European Journal of Heart Failure, vol. 15, no.
1, pp.110–118, 2013.163.Yip G. The Hong Kong diastolic heart failure study: a randomisedcontrolled trial of diuretics, irbesartan and ramipril on quality of life, exercisecapacity, left ventricular global and regional function in heart failure with anormal ejection fraction /Yip G., Wang M., Wang T., et al. // Heart, vol. 94, no.5, pp. 573–580, 2008.164.Yusuf S. Effects of candesartan in patients with chronic heart failure andpreserved left ventricular ejection fraction: the CHARM- Preserved Trial / YusufS., Pfeffer M., et al.
// Lancet. 2003; 362: 777–781.126165.Zakeri R. Impact of atrial fibrillation on exercise capacity in heart failurewith preserved ejection fraction: a RELAX trial ancillary study / Zakeri R.,Borlaug B., McNulty S., et al. // Circ Heart Fail. 2014; 7:123–130166.Zannad F. Eplerenone in patients with systolic heart failure and mildsymptoms / Zannad F., McMurray J., Krum H., et al.
// N Engl J Med 2011; 364:11–21167.Zile M. Heart failure with a normal ejection fraction: is measurement ofdiastolic function necessary to make the diagnosis of diastolic heart failure? /ZileM., Gaasch W., Carroll J., et al. // Circulation. 2001 Aug 14;104(7):779–82.168.Zhao L. Why atrial fibrillation recurs in patients who obtained currentablation endpoints with longstanding persistent atrial fibrillation / Zhao L., JiangW., Zhou L., et al. // J Interv Card Electrophysiol. 2013 Sep; 37 (3):283–90.169.Zoni-Berisso M. Epidemiology of atrial fibrillation: European perspective /Zoni-Berisso M., Lercari F., Carazza T., et al // Clin Epidemiol. 2014 Jun16;6:213–20.127СПИСОК ТАБЛИЦТаблица 1. Характеристика больных, включенных в исследование .......................... 30Таблица 2. Характеристика операций ...........................................................................
37Таблица 3. Антопометрические данные пациентов с пароксизмальной иперсистирующей формами ФП ...................................................................................... 40Таблица 4. Распределение пациентов по классам шкалы EHRA до операции ичерез 12 месяцев в группе II ........................................................................................... 41Таблица 5. Показатели диастолической функции ЛЖ и размеры ЛП, взависимости от формы ФП, полученные по данным МСКТ и эхокардиографии ....
42Таблица 6. Сравнение диастолических показателей в зависимости от типаизоляции ЛВ..................................................................................................................... 43Таблица 7. Предоперационные МСКТ-параметры ЛП в группах эффективного инеэффективного вмешательства .................................................................................... 46Таблица 8. Сравнение показателей ЛП по данным эхокардиографии и МСКТангиографии на старте исследования ............................................................................ 46Таблица 9.
Сравнение диастолических показателей между пациентами спромежуточным состоянием, отсутствием и наличием ДДЛЖ ................................. 49Таблица 10. Распределение типов нарушения диастолической функции дооперации, через 6 и 12 мес. ............................................................................................ 50Таблица 11. Диастолические параметры и показатели ЛП в группах больных сДДЛЖ и без нее перед катетерной изоляцией ЛВ .......................................................
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
